106 related articles for article (PubMed ID: 3713304)
21. [Visceral leishmaniasis (kala-azar): 1st case observed in Chile].
Osorio G; Moyano C; Caravagno C; Miranda C; Ubilla M; Maturana G; Retamales I
Rev Med Chil; 1984 Mar; 112(3):261-6. PubMed ID: 6473968
[No Abstract] [Full Text] [Related]
22. Does antimony therapy cause bleeding in kala-azar patients and why?
Chowdhury MA; Ahasan HA; Azhar MA; Rafiqueuddin AK; Islam MR; Misbahuddin M; Rashid MU
Trop Doct; 1995 Oct; 25(4):188-9. PubMed ID: 7502336
[No Abstract] [Full Text] [Related]
23. [Kala-azar and autoimmune hemolytic anemia. Apropos of a fatally developing case caused by hepatotoxicity from N-methylglucamine antimonate].
De Pablos Gallego JM; Cabrera Torres A; Almagro M; De Puerta S; López Garrido P; Gómez Morales M; Esquivias JJ
Rev Clin Esp; 1982 Mar; 164(6):417-20. PubMed ID: 7111811
[No Abstract] [Full Text] [Related]
24. Antimony containing drug and ECG abnormalities in children with visceral leishmaniasis.
Zanoni LZ; Brustoloni YM; Melnikov P; Cônsolo CE
Biol Trace Elem Res; 2009 Dec; 132(1-3):35-40. PubMed ID: 19424667
[TBL] [Abstract][Full Text] [Related]
25. Atypical disseminated leishmaniasis resembling post-kala-azar dermal leishmaniasis in an HIV-infected patient.
Boumis E; Chinello P; Della Rocca C; Paglia MG; Proietti MF; Petrosillo N
Int J STD AIDS; 2006 May; 17(5):351-3. PubMed ID: 16643688
[TBL] [Abstract][Full Text] [Related]
26. Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: a report of 13 cases in the southwestern region of Brazil.
Oliveira AL; Brustoloni YM; Fernandes TD; Dorval ME; Cunha RV; Bóia MN
Trop Doct; 2009 Jul; 39(3):180-2. PubMed ID: 19535762
[TBL] [Abstract][Full Text] [Related]
27. Pediatric visceral leishmaniasis in Western Sicily, Italy: a retrospective analysis of 111 cases.
Cascio A; Colomba C; Antinori S; Orobello M; Paterson D; Titone L
Eur J Clin Microbiol Infect Dis; 2002 Apr; 21(4):277-82. PubMed ID: 12072938
[TBL] [Abstract][Full Text] [Related]
28. [Two cases of kala-azar treated with glucantime].
MATOS J; VELASCO JA
Acta Pediatr Esp; 1955 Nov; 13(155):959-63. PubMed ID: 13301754
[No Abstract] [Full Text] [Related]
29. [Diagnosis and treatment of kala-azar].
Neves J
Rev Paul Med; 1983; 101(6):237-9. PubMed ID: 6677985
[No Abstract] [Full Text] [Related]
30. Treatment of paediatric visceral leishmaniasis: amphotericin B or pentavalent antimony compounds?
Kafetzis DA; Velissariou IM; Stabouli S; Mavrikou M; Delis D; Liapi G
Int J Antimicrob Agents; 2005 Jan; 25(1):26-30. PubMed ID: 15620822
[TBL] [Abstract][Full Text] [Related]
31. [Neurological toxicity from pentavalent antimonials during the treatment of visceral leishmaniasis].
Laguna del Estal P; Calabrese S; Zabala JA; Martín T
Med Clin (Barc); 1994 Feb; 102(7):276-7. PubMed ID: 8170219
[No Abstract] [Full Text] [Related]
32. A case report of Kala-Azar in a kidney transplant patient.
Malek Hosseini SA; Javid R; Salahi H; Nezakatgoo N; Ahmad E; Ghahramani N
Transplant Proc; 1995 Oct; 27(5):2715. PubMed ID: 7482886
[No Abstract] [Full Text] [Related]
33. [Value of the ELISA IgG and IgM test in the diagnosis and post-therapeutic monitoring of kala-azar].
Ben Said M; Ben Rachid MS
Ann Soc Belg Med Trop; 1985; 65(1):31-40. PubMed ID: 3890778
[No Abstract] [Full Text] [Related]
34. Post-kala-azar dermal leishmaniasis.
Baghestani S; Handjani F; Sodeifi M; Kumar PV
Eur J Dermatol; 1998 Jun; 8(4):277-9. PubMed ID: 9649686
[TBL] [Abstract][Full Text] [Related]
35. [Clinico-epidemiological study of kala-azar in the south of Madrid].
de la Serna FJ; Salto E; Valdés D; Vos Saus R
Rev Sanid Hig Publica (Madr); 1987; 61(7-8):783-98. PubMed ID: 3438697
[No Abstract] [Full Text] [Related]
36. [Renal function in patients with mucocutaneous leishmaniasis treated with pentavalent antimony compounds].
Veiga JP; Rosa TT; Kimachi T; Wolff ER; Sampaio RN; Gagliardi AR; Junqueira Júnior LF; Costa JM; Marsden PD
Rev Inst Med Trop Sao Paulo; 1985; 27(6):298-302. PubMed ID: 3014634
[No Abstract] [Full Text] [Related]
37. PKDL--a drug related phenomenon?
Croft SL
Indian J Med Res; 2008 Jul; 128(1):10-1. PubMed ID: 18820352
[No Abstract] [Full Text] [Related]
38. [Glucantime reaction with fatal outcome following treatment of cutaneous leishmaniasis].
Hajlaoui K; Zeglaoui F; Ezzine N; Kastalli S; Elfekih N; Fazaa B; Loueslati MH; Kamoun MR
Ann Dermatol Venereol; 2008 Apr; 135(4):317-8. PubMed ID: 18420083
[No Abstract] [Full Text] [Related]
39. [Electrocardiographic evaluation of the cardiotoxicity of N-methylglucamine antimonate (R glucantime)].
García Muller R; Valera M; Carrasco H; Fuenmayor A; Ramírez Benedetti J; Torrealba W; Mendoza E
Arch Inst Cardiol Mex; 1982; 52(2):155-9. PubMed ID: 7103604
[TBL] [Abstract][Full Text] [Related]
40. Severe arthralgia, not related to dose, associated with pentavalent antimonial therapy for mucosal leishmaniasis.
Castro C; Sampaio RN; Marsden PD
Trans R Soc Trop Med Hyg; 1990; 84(3):362. PubMed ID: 2260169
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
